EA201591259A1 - Твёрдые формы производного хиназолина и их применение в качестве ингибитора braf - Google Patents

Твёрдые формы производного хиназолина и их применение в качестве ингибитора braf

Info

Publication number
EA201591259A1
EA201591259A1 EA201591259A EA201591259A EA201591259A1 EA 201591259 A1 EA201591259 A1 EA 201591259A1 EA 201591259 A EA201591259 A EA 201591259A EA 201591259 A EA201591259 A EA 201591259A EA 201591259 A1 EA201591259 A1 EA 201591259A1
Authority
EA
Eurasian Patent Office
Prior art keywords
application
solid forms
hinazolin
derivative
braf inhibitor
Prior art date
Application number
EA201591259A
Other languages
English (en)
Other versions
EA025561B1 (ru
Inventor
Стефен Дж. Бирлмайер
Ральф К. Холтивангер
Мартин Дж. Джейкобс
Original Assignee
Игнита, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Игнита, Инк. filed Critical Игнита, Инк.
Publication of EA201591259A1 publication Critical patent/EA201591259A1/ru
Publication of EA025561B1 publication Critical patent/EA025561B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящая заявка относится к различным солям и твёрдым формам соединения I. Настоящая заявка также относится к фармацевтическим композициям и способам терапевтического применения указанных веществ и композиций.
EA201591259A 2013-03-11 2014-03-11 Твёрдые формы производного хиназолина и их применение в качестве ингибитора braf EA025561B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361776081P 2013-03-11 2013-03-11
PCT/US2014/023110 WO2014164648A2 (en) 2013-03-11 2014-03-11 Solid state forms of a quinazoline derivative and its use as a braf inhibitor

Publications (2)

Publication Number Publication Date
EA201591259A1 true EA201591259A1 (ru) 2016-02-29
EA025561B1 EA025561B1 (ru) 2017-01-30

Family

ID=50771322

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591259A EA025561B1 (ru) 2013-03-11 2014-03-11 Твёрдые формы производного хиназолина и их применение в качестве ингибитора braf

Country Status (15)

Country Link
US (3) US9353097B2 (ru)
EP (1) EP2956454A2 (ru)
JP (1) JP2016512516A (ru)
KR (1) KR20150132118A (ru)
CN (1) CN105051039A (ru)
AU (2) AU2014249158B2 (ru)
BR (1) BR112015022207A8 (ru)
CA (1) CA2901204C (ru)
EA (1) EA025561B1 (ru)
HK (2) HK1217193A1 (ru)
IL (1) IL241239A0 (ru)
MX (1) MX2015012318A (ru)
NZ (1) NZ710600A (ru)
TW (1) TW201512192A (ru)
WO (1) WO2014164648A2 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015012318A (es) 2013-03-11 2016-04-15 Ignyta Inc Formas de estado solido de un derivado de quinazolina y su uso como un inhibidor de braf.
WO2018102455A1 (en) * 2016-12-01 2018-06-07 Ignyta, Inc. Methods for the treatment of cancer
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CN111153860B (zh) * 2019-12-30 2021-06-29 广州六顺生物科技股份有限公司 一种喹唑啉类化合物的晶型及其制备方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070244120A1 (en) * 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
DK2268623T3 (en) * 2008-03-17 2015-06-29 Ambit Biosciences Corp QUINAZOLINE DERIVATIVES AS RAF CHINESE MODULATORS AND PROCEDURES FOR USE THEREOF
AU2012240240A1 (en) * 2011-04-04 2013-05-09 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
MX2015012318A (es) 2013-03-11 2016-04-15 Ignyta Inc Formas de estado solido de un derivado de quinazolina y su uso como un inhibidor de braf.

Also Published As

Publication number Publication date
US9987281B2 (en) 2018-06-05
WO2014164648A4 (en) 2015-01-29
EA025561B1 (ru) 2017-01-30
CA2901204A1 (en) 2014-10-09
US9718810B2 (en) 2017-08-01
TW201512192A (zh) 2015-04-01
AU2014249158A1 (en) 2015-09-17
JP2016512516A (ja) 2016-04-28
AU2016204294B9 (en) 2017-09-21
WO2014164648A3 (en) 2014-11-27
IL241239A0 (en) 2015-11-30
BR112015022207A2 (pt) 2017-07-18
EP2956454A2 (en) 2015-12-23
CN105051039A (zh) 2015-11-11
NZ710600A (en) 2017-01-27
US20170290833A1 (en) 2017-10-12
HK1217333A1 (zh) 2017-01-06
BR112015022207A8 (pt) 2018-01-23
AU2014249158B2 (en) 2016-07-28
US9353097B2 (en) 2016-05-31
HK1217193A1 (zh) 2016-12-30
AU2016204294A1 (en) 2016-07-14
US20150376171A1 (en) 2015-12-31
MX2015012318A (es) 2016-04-15
KR20150132118A (ko) 2015-11-25
AU2016204294B2 (en) 2017-08-31
WO2014164648A2 (en) 2014-10-09
US20160280698A1 (en) 2016-09-29
CA2901204C (en) 2018-07-10

Similar Documents

Publication Publication Date Title
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
EA201890239A3 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201690598A1 (ru) Аминогетероарил бензамиды в качестве ингибиторов киназы
EA201891553A1 (ru) Ингибиторы syk
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201790661A3 (ru) Ингибиторы вируса гепатита c
EA201500801A1 (ru) Бензохинолоновые ингибиторы vmat2
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201391285A1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
EA201692480A1 (ru) Фармацевтическая композиция
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
EA201890331A1 (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
EA201591360A1 (ru) Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
EA201791293A1 (ru) Сайт-специфическое дозирование ингибитора btk
EA201690844A1 (ru) Ингибиторы gsk-3
EA201500931A1 (ru) Производные пиридин-4-ила
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU